Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neutropenia 5Breast Neoplasms 5Febrile Neutropenia 3Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Malignant Solid Tumors 1Lymphoma 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breastcancer 1Breast Cancer Female 1

Interventions

Exercise 3Paclitaxel 2Cyclophosphamide 2Control Groups 2Capecitabine 2Bupivacaine 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1palbociclib 1iniparib 1darolutamide 1Yoga 1Waiting Lists 1Vitamin D 1Thioctic Acid 1Surveys and Questionnaires 1Sodium Chloride 1Ropivacaine 1Radiofrequency Ablation 1Neoadjuvant Therapy 1Methotrexate 1Metformin 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Electrochemotherapy 1Educational Status 1Drug Delivery Systems 1Doxorubicin 1Diet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Cancer Female × pegylated granulocyte colony-stimulating factor × Clear all
NCT04554056 2022-12-02

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2/3 Completed
586 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡